CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Dong, Yuan Lin ^a   Kabir, Syeda M ^a   Lee, Eun Sook ^a   Son, Deok Soo ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; CHEMOKINE; EGFR PROTEIN, HUMAN; LIGAND; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL MOTION; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PROMOTER REGION; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CXCL1; CHEMOKINES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIGANDS; NEOPLASM INVASIVENESS; NF-KAPPA B; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, INTERLEUKIN-8B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84893443618     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083789     Document Type: Article

References (44)

1. Chobanian N, Dietrich CS (2008) Ovarian cancer. Surg Clin North Am 88:285-299. (Pubitemid 351434416)
2. Dobrzycka B, Terlikowski SJ, Kowalczuk O, Kinalski M (2009) Circulating levels of TNF-α and its soluble receptors in the plasma of patients with epithelial ovarian cancer. Eur Cytokine Netw 20:131-134.
3. Macciò A, Madeddu C (2012) Inflammation and ovarian cancer. Cytokine 58:133-147.
4. Szlosarek PW, Grimshaw MJ, Kulbe H, Wilson JL, Wilbanks GD, et al. (2006) Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 5:382-390.
5. Son DS, Parl AK, Rice VM, Khabele D (2007) Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biol Ther 6:1302-1312. (Pubitemid 351590387)
6. Son DS, Kabir SM, Dong YL, Lee E, Adunyah SE (2012) Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB. PLoS One 7:e51116.
7. Balkwill FR (2012) The chemokine system and cancer. J Pathol 226:148-157.
8. Singh R, Lillard JW Jr, Singh S (2011) Chemokines: key players in cancer progression and metastasis. Front Biosci 3:1569-1582.
9. Yang G, Rosen DG, Liu G, Yang F, Guo X, et al. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16:3875-3886.
10. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, et al. (2013) CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73:571-582.
11. Han L, Jiang B, Wu H, Wang X, Tang X, et al. (2012) High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol 29:2466-2472.
12. Ewington L, Taylor A, Sriraksa R, Horimoto Y, Lam EW, et al. (2012) The expression of interleukin-8 and interleukin-8 receptors in endometrial carcinoma. Cytokine 59: 417-422.
13. Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, et al. (2013) Interleukin genes and associations with colon and rectal cancer risk and overall survival. Int J Cancer 132:905-915.
14. Liu Z, Yang L, Xu J, Zhang X, Wang B (2011) Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res 166:241-246.
15. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, et al. (2011) Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 22:2267-2276.
16. Shen H, Schuster R, Lu B, Waltz SE, Lentsch AB (2006) Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 66:1721-1728. (Pubitemid 44893898)
17. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM (2004) Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172:2853-2860. (Pubitemid 38263670)
18. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, et al. (2005) The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 175:5351-5357. (Pubitemid 41456421)
19. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, et al. (2012) Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 122:3127-3144.
20. Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, et al. (2012) Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106:1833-1841.
21. Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, et al. (2011) The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer 104:480-487.
22. Olson TS, Ley K (2002) Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283:R7-R28. (Pubitemid 34863907)
23. Son DS, Roby KF (2006) Interleukin-1α-induced chemokines in mouse granulosa cells: impact on keratinocyte chemoattractant chemokine, a CXC subfamily. Mol Endocrinol 20:2999-3013.
24. Jiang T, Soprano DR, Soprano KJ (2007) GADD45A is a mediator of CD437 induced apoptosis in ovarian carcinoma cells. J Cell Physiol 212:771-779. (Pubitemid 47267546)
25. Yang F, Zhang W, Li D, Zhan Q (2013) Gadd45α suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 pathway. J Biol Chem 288:6552-6560.
26. Shan Z, Li G, Zhan Q, Li D (2012) Gadd45a inhibits cell migration and invasion by altering the global RNA expression. Cancer Biol Ther 13:1112-1122.
27. Bolitho C, Hahn MA, Baxter RC, Marsh DJ (2010) The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer 17:929-940.
28. Seppänen M, Lin L, Saarinen R, Punnonen R, Vihko KK (2008) Regulation of ovarian UT-OC-2 carcinoma cells by cytokines: effects on cell proliferation, activation of transcription factors and apoptosis. Acta Obstet Gynecol Scand 87:902-909.
29. Kim DS, Jang YJ, Jeon OH, Kim DS (2007) Saxatilin inhibits TNF-α-induced proliferation by suppressing AP-1-dependent IL-8 expression in the ovarian cancer cell line MDAH 2774. Mol Immunol 44:1409-1416. (Pubitemid 44415952)
30. Tront JS, Huang Y, Fornace AJ Jr, Hoffman B, Liebermann DA (2010) Gadd45a functions as a promoter or suppressor of breast cancer dependent on the oncogenic stress. Cancer Res 70:9671-9681.
31. Fayolle C, Pourchet J, Caron de Fromentel C, Puisieux A, Doré JF, et al. (2008) Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol 128:196-202. (Pubitemid 350249379)
32. Lin CR, Yang CH, Huang CE, Wu CH, Chen YS, et al. (2011) GADD45A protects against cell death in dorsal root ganglion neurons following peripheral nerve injury. J Neurosci Res 89:689-699.
33. Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, et al. (2011) Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog 16: 129-140.
34. Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, et al. (2012) The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Mol Cancer Ther 11:1353-1364.
35. von Vietinghoff S, Asagiri M, Azar D, Hoffmann A, Ley K (2010) Defective regulation of CXCR2 facilitates neutrophil release from bone marrow causing spontaneous inflammation in severely NF-κB- deficient mice. J Immunol 185:670-678.
36. Benelli R, Stigliani S, Minghelli S, Carlone S, Ferrari N (2013) Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate 73:941-951.
37. Takamori H, Oades ZG, Hoch OC, Burger M, Schraufstatter IU (2000) Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 21:52-56. (Pubitemid 30421934)
38. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, et al. (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150:165-178.
39. Wang B, Hendricks DT, Wamunyokoli F, Parker MI (2006) A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 66:3071-3077.
40. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, et al. (2010) Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 70:5880-5890.
41. Kuo PL, Shen KH, Hung SH, Hsu YL (2012) CXCL1/GROα increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-κB/HDAC1 epigenetic regulation. Carcinogenesis 33:2477-2487.
42. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS (2007) Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56:25-33. (Pubitemid 46356635)
43. Yang RH, Strong JA, Zhang JM (2009) NF-κB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. Mol Pain 5:26.
44. Ogata H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, et al. (2010) GROa promotes invasion of colorectal cancer cells. Oncol Rep 24:1479-1486.